ISIS-4

ISIS-4

Cardiology A clinical trial–International Study of Infarct Survival that compared medical therapies–eg, oral captopril, oral mononitrate, IV magnesium on M&M in Pts with suspected acute MI. See Acute myocardial infarction, Streptokinase.
References in periodicals archive ?
Peter Held, Goteberg University, Goteberg, Denmark, speaking on behalf of the ISIS-4 study group, stated the the nitrate formulation Imdur was selected for the ISIS-4 trial because of its once-daily regimen, proven long-term efficacy for agina, avoidance of drug tolerance and rebound, bioavailability unaffected by food, and flexible dosing ability due to its easily divisible tablet form.
Peter Sleight, chairman of the ISIS-4 Steering Committee, "I would certainly use nitrates, especially oral nitrates, for more symptomatic patients.
In ISIS-4, captopril showed a small but significant reduction in mortality, with five lives per thousand.
The drug is licensed from Astra Hassle AB, Sweden, which helped finance the ISIS-4 trial with a grant to the University of Oxford, England, the sponsoring institution.